MedTrace Logo

Efficacy of Donepezil in Patients With Chronic Tinnitus

NCT07153991 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2025-09-04

No results posted yet for this study

Summary

This study is a prospective, placebo-controlled, randomized, double-blind clinical trial, including 70 patients with chronic sensorineural tinnitus, divided into placebo and treatment groups. Participants received donepezil for 3 months, starting with 5 mg daily for the first month and 10 mg daily for the following two months.

Conditions

  • Tinnitus

Interventions

DRUG

Donepezil group

Participants received donepezil for 3 months, starting with 5 mg daily for the first month and 10 mg daily for the following two months

DRUG

Placebo group

35 Pacients with tinnitus received for 3 months placebo medication

Sponsors & Collaborators

  • Fundação de Amparo à Pesquisa do Estado de São Paulo

    collaborator OTHER_GOV

  • University of Sao Paulo

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-19
Primary Completion
2025-12-09
Completion
2025-12-09
FDA Drug
Yes

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07153991 on ClinicalTrials.gov